Table 1. Source, dilution and cut-off values for positivity for different biomarkers.
Marker | Antibody (Source) | Optimal dilution | Positive-control tissue | Cut-off values for positivity |
---|---|---|---|---|
ck5/6 | D5/16 B4 (Dako UK Ltd, Ely, Cambridgeshire, UK) | 1 : 100 | Tonsil | 10% |
ck14 | LL002 (Vector Labs, Peterborough, UK) | 1 : 100 | Skin | 10% |
ER | 1D5 (Dako UK Ltd) | 1 : 100 | Breast | 1% |
PGR | PGR 636 (Dako UK Ltd) | Neat | Breast | 1% |
HER2 | DakoA0485 (Dako UK Ltd) | 1 : 500 | Breast | 30% membranous (corresponds to IHC 3+), or if IHC 2+, confirmed by FISH+ |
p53 | DO7 (Dako UK Ltd) | 1 : 100 | Breast | 10% nuclear |
EGFR | EGFR.113 (Dako UK Ltd) | 1 : 50 | Skin | 10% membranous |
Topo2α | KI-S1 (Dako UK Ltd) | 1 : 100 | Tonsil | 45% nuclear (high) |
KI67 | MIB1 (Dako UK Ltd) | 1 : 100 | Tonsil | 10% nuclear (high) |
Positive-control tissue is also indicated. Positive HER2 was defined as presence of membrane expression of the protein in >30% of tumour cells (corresponds to IHC 3+) or if underexpressed (2+), confirmed by FISH (fluorescent in situ hybridisation). For p53, Topo2α and Ki67, 100 nuclei were scored for positivity in four random fields ( × 40 magnification) and the total percent-score obtained. Median values of Topo2α were chosen as cut-offs for high or low expression. Other standard cut-offs as per Rakha et al (2006, 2007).